

CEQUA™ (cyclosporine) – New drug approval

- On August 16, 2018, [Sun Pharma announced](#) the FDA approval of [CEQUA \(cyclosporine \[CsA\]\)](#), to increase tear production in patients with keratoconjunctivitis sicca (dry eye).
- Dry eye disease occurs when the quantity and/or quality of tears fails to keep the surface of the eye properly lubricated. The disease causes a scratchy sensation or a feeling that something is in the eye. Other symptoms include stinging or burning, episodes of excess tearing following periods of stress, discharge, pain, and redness in the eye.
 - Greater than 16 million patients are affected by dry eye disease in the U.S.
- CEQUA is a calcineurin inhibitor immunosuppressant that provides a nanomicellar formulation of CsA. The small size of the nanomicelles facilitates entry into corneal and conjunctival cells, enabling delivery of high concentrations of CsA.
- CsA is also available as the ophthalmic emulsions [Restasis®](#) and [Restasis Multidose™](#).
 - Both Restasis products contain cyclosporine 0.5 mg/mL and are indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.
- The efficacy of CEQUA was demonstrated in two vehicle-controlled studies enrolling 1,048 patients with keratoconjunctivitis sicca for 84 days.
 - In the first study, 16.8% of eyes treated with CEQUA vs. 8.6% of eyes treated with vehicle experienced ≥ 10 -mm increase in tear production (difference: 8.2% [95% CI: 1.9%, 14.6%]; $p < 0.01$).
 - In the second study, 16.6% of eyes treated with CEQUA vs. 9.2% of eyes treated with vehicle experienced ≥ 10 -mm increase in tear production (difference: 7.3% [95% CI: 3.3%, 11.3%]; $p < 0.01$).
- Warnings and precautions of CEQUA include potential for eye injury and contamination and use with contact lenses.
- The most common adverse reactions with CEQUA use were instillation site pain (22%) and conjunctival hyperemia (6%).
- The recommended dosage of CEQUA is one drop instilled twice daily (approximately 12 hours apart) into each eye.
 - CEQUA can be used concomitantly with artificial tears, allowing a 15-minute interval between products.
 - Discard the vial immediately after using in both eyes.

- Sun Pharma's launch plans for CEQUA are pending. CEQUA will be available as a 0.09% ophthalmic solution in preservative-free, single-use vials.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.